This Federal Circuit opinion analyzes lexicography in the context of claim construction.
Alnylam Pharmaceuticals owns U.S. Patent Nos. 11,246,933 (parent) and 11,382,979 (child). These patents relate to biodegradable...more
7/22/2025
/ Biotechnology ,
Claim Construction ,
Coronavirus/COVID-19 ,
Intellectual Property Protection ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
USPTO ,
Vaccinations